Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 10/20 | 0.66 |
| ▸ | MMP13 | P45452 | 9/20 | 0.66 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27540111 | 1.00 | MMP12 (0.66) | MMP12MMP13KEAP1BCAT1HDAC1 | |
| SCHEMBL6416012 | 0.91 | MMP13 (0.64) | MMP12MMP13KEAP1BCAT1HDAC1 | |
| SCHEMBL6414491 | 0.89 | MMP12 (0.67) | MMP12MMP13KEAP1BCAT1HDAC1 | |
| SCHEMBL6413671 | 0.88 | MMP12 (0.69) | MMP12MMP13KEAP1BCAT1HTT | |
| SCHEMBL6419152 | 0.88 | MMP12 (0.66) | MMP12MMP13KEAP1BCAT1HDAC1 | |
| SCHEMBL6342584 | 0.88 | MMP12 (0.66) | MMP12MMP13KEAP1BCAT1HDAC1 | |
| SCHEMBL28747284 | 0.88 | MMP12 (0.66) | MMP12MMP13KEAP1BCAT1HDAC1 | |
| SCHEMBL27542487 | 0.87 | MMP13 (0.65) | MMP12MMP13ALDH1A1POLBLMNA | |
| SCHEMBL4425847 | 0.87 | MMP13 (0.65) | MMP12MMP13ALDH1A1POLBLMNA | |
| SCHEMBL7352062 | 0.86 | MMP12 (0.64) | MMP12MMP13KEAP1PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0931045-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1999-07-28 | — | — | EP | claimed |
| WO-1998009934-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | claimed |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| EP-1851197-A2 | PHENYLAZETIDINONE DERIVATIVES | Microbia, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006102674-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006086562-A2 | PHENYLAZETIDINONE DERIVATIVES | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| US-6906092-B2 | Method of inhibiting matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040029945-A1 | Method of inhibiting matrix metalloproteinases | O'BRIEN PATRICK MICHAEL (US) | 2004-02-12 | — | — | US | disclosed |
| US-6624177-B1 | Treating diseases in which matrix melatoproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6620835-B2 | Sulfonamide-substituted benzothiophenes (that may be oxidized), carbazoles, fluorenes and fluorenones | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-20030032665-A1 | Method of inhibiting matrix metalloproteinases | O'BRIEN PATRICK MICHAEL (US) | 2003-02-13 | — | — | US | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| EP-0931045-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998009934-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032665-A1 | Method of inhibiting matrix metalloproteinases | MMP17, MMP1, MMP12 | MMP12 3/4885MMP13 11/4885KEAP1 1908/4885 |
| US-20040029945-A1 | Method of inhibiting matrix metalloproteinases | MMP17, MMP1, MMP12 | MMP12 3/4885MMP13 11/4885KEAP1 1908/4885 |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | NPC1L1, CYP46A1, NPC1 | MMP12 2427/4885MMP13 4390/4885KEAP1 1419/4885 |
| US-20090005321-A1 | Phenylazetidinone Derivatives | TYR, AAAS, FANCD2 | MMP12 3804/4885MMP13 4166/4885KEAP1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.